Compare Cipher Mining Inc (CIFR) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cipher Mining Inc vs Novo Nordisk A/S — how do they compare? Cipher Mining Inc trades at $17.96 (market cap $7.14B), while Novo Nordisk A/S trades at $46.43 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 29.1× Cipher Mining Inc's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Cipher Mining Inc pays none. Which is the better fit depends on your goals.
| CIFR | NVO | |
|---|---|---|
Market Cap | $7.14B | $207.85B |
Sector | Basic Materials | Health |
52-Week High | $29.18 | $63.98 |
52-Week Low | $4.72 | $35.29 |
Enterprise Value | $11.90B | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CIFR trades at $17.87, up 9.43% in 24 hours, but remains in a bearish technical trend with significant fundamental challenges. The company reported a Q2 2026 loss of $0.65 per share, missing estimates, with revenue of $191 million and a net loss of $1.1 billion. Despite negative profitability metrics, analyst consensus is unanimously bullish with a $31.78 price target, citing progress in transitioning from Bitcoin mining to AI data center operations.
The outlook hinges on successful execution of its AI infrastructure pivot, but high valuation ratios and persistent losses pose substantial risks. Near-term support lies at $16, while resistance is at $18. Investor sentiment is divided between optimism over AI contracts and concerns over cash burn and mining dependency.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cipher Mining Inc
Cipher Mining is an industrial-scale technology company focused on Bitcoin mining infrastructure. It develops and operates data centers in the US designed to strengthen the Bitcoin network and support decentralized finance.
Read more on CIFR →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
